Press Releases

08-07-2024	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
08-06-2024	Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
07-15-2024	Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
06-13-2024	Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
06-12-2024	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06-06-2024	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
05-21-2024	Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
05-14-2024	Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
05-07-2024	Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
05-06-2024	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results